Edition:
United States

Alpine Immune Sciences Inc (ALPN.OQ)

ALPN.OQ on NASDAQ Stock Exchange Global Market

6.45USD
1:15pm EDT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$6.45
Open
$6.45
Day's High
$6.50
Day's Low
$6.44
Volume
4,332
Avg. Vol
5,478
52-wk High
$12.82
52-wk Low
$5.44

Chart for

About

Alpine Immune Sciences, Inc., formerly Nivalis Therapeutics, Inc., is focused on developing a protein-based immunotherapies using Variant immunoglobulin domain (vlgD) platform technology. The vlgD platform is designed to interact with multiple targets, including many present in the immune synapse. The vlgDs are developed using a... (more)

Overall

Beta: --
Market Cap(Mil.): $89.34
Shares Outstanding(Mil.): 13.85
Dividend: --
Yield (%): --

Financials

  ALPN.OQ Industry Sector
P/E (TTM): -- 108.45 32.71
EPS (TTM): -0.91 -- --
ROI: -22.82 1.54 12.72
ROE: -23.46 0.30 14.84

BRIEF-Alpine Immune Sciences Qtrly Loss Per Share $0.38

* ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 14 2018

BRIEF-Alpine Immune Sciences Appoints Chris Peetz To Its Board

* ALPINE IMMUNE SCIENCES APPOINTS LIFE SCIENCES EXECUTIVE CHRIS PEETZ TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

Apr 24 2018

BRIEF-Alpine Immune Sciences Provides Corporate Update And Reports Full Year 2017 Financial Results

* ALPINE IMMUNE SCIENCES PROVIDES CORPORATE UPDATE AND REPORTS FULL YEAR 2017 FINANCIAL RESULTS

Mar 28 2018

Earnings vs. Estimates